AVITA Medical Reports Third Quarter 2022 Financial Results
10 nov. 2022 16h01 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and...
AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair
09 nov. 2022 18h45 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System
03 nov. 2022 20h15 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical to Announce Third Quarter 2022 Financial Results
20 oct. 2022 16h01 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Oct. 20, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer
28 sept. 2022 19h06 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
Investor Webinar Briefing
13 sept. 2022 16h11 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL® System
12 sept. 2022 16h23 HE
|
AVITA Medical
The study achieved its primary effectiveness endpoint of super-superiority AVITA Medical continues to plan for submission to FDA by the end of 2022 VALENCIA, Calif. and MELBOURNE, Australia, Sept. ...
RECELL System Insurance Coverage Begins in Japan for Treatment of Acute Burns
01 sept. 2022 08h00 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
RECELL® System Data to be Presented at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting
17 août 2022 16h50 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Aug. 17, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical Reports Second Quarter 2022 Financial Results
11 août 2022 16h06 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and...